Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023)

Spyre Therapeutics has reported Capital Expenditures for 9 years, with the latest figure at -$2.1 million in Q3 2023.

• For the quarter ending Q3 2023, Capital Expenditures fell 206800.0% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2023 stood at -$2.1 million (down 5536.84% YoY), and the FY2022 full-year result was $38000.0, down 93.37% from the prior year.
• Capital Expenditures for Q3 2023 stood at -$2.1 million, down from $1000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $2.8 million in Q3 2020, with the low at -$2.1 million in Q3 2023.
• Historically, Capital Expenditures has averaged $227142.9 across 5 years, with a median of $87500.0 in 2019.
• Annual changes were most pronounced in 2020 — Capital Expenditures jumped 2531.58% — and 2023, when it slumped 206800.0%.
• Spyre Therapeutics' Capital Expenditures stood at $38000.0 in 2019, then jumped by 2531.58% to $1.0 million in 2020, then slumped by 45.0% to $550000.0 in 2021, then sank by 99.82% to $1000.0 in 2022, then tumbled by 206800.0% to -$2.1 million in 2023.
• The last three Capital Expenditures figures came in at -$2.1 million (Q3 2023), $1000.0 (Q3 2022), and $37000.0 (Q1 2022), per Business Quant data.